Specifically, in the Inova cohort with 50 melanoma patients treated with anti-PD-(L)1 plus anti-CTLA4, 25 patients were defined as SpHe-comut+, and those patients had a significantly longer PFS (median PFS, SpHe-comut+ not reached (NR) vs. SpHe-comut− 7.5 months; HR, 0.27; 95% CI, 0.11–0.64; log-rank test p = 0.002; Fig. 5A). Here, CTLA4 is linked to melanoma.